Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senti Biosciences HoldingsSNTI -10.12%18 3-1 Month Momentum % is -65.27% as of Sep. 02, 2026. GuruFocus rates SNTI with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 1,379 Biotechnology companies, Senti Biosciences Holdings ranks worse than 96.88% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-02), Senti Biosciences Holdings's 3-1 Month Momentum % is -65.27%.
The industry rank for Senti Biosciences Holdings's 3-1 Month Momentum % or its related term are showing as below:
SNTI's 3-1 Month Momentum % is ranked worse than 96.88% of 1379
companies
in the Biotechnology industry
Industry Median: -10.27
vs SNTI: -65.27
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Senti Biosciences Holdings 3-1 Month Momentum % Related Terms
SNTI vs KPRX, PDSB, TOVX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Senti Biosciences Holdings's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senti Biosciences Holdings 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Senti Biosciences Holdings's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senti Biosciences Holdings (SNTI) has a 3-1 Month Momentum % of -65.27% as of Sep. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Senti Biosciences Holdings and its competitors. According to the industry distribution chart, Senti Biosciences Holdings ranks #1336 out of 1379 companies in the Biotechnology industry, placing it in the top 96.9%.
Is Senti Biosciences Holdings' 3-1 Month Momentum % too high?
Senti Biosciences Holdings' current 3-1 Month Momentum % is -65.27%. Based on the distribution chart, Senti Biosciences Holdings ranks #1336 out of 1379 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Senti Biosciences Holdings has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Senti Biosciences Holdings' 3-1 Month Momentum % compare to KPRX and PDSB?
According to the Biotechnology industry distribution chart, Senti Biosciences Holdings ranks #1336 out of 1379 companies for 3-1 Month Momentum %. This places Senti Biosciences Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Senti Biosciences Holdings and its competitors. Senti Biosciences Holdings's current 3-1 Month Momentum % is -65.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senti Biosciences Holdings stock overvalued right now?
Senti Biosciences Holdings (SNTI) has a current 3-1 Month Momentum % of -65.27%. The current 3-1 Month Momentum % is -65.27%. Senti Biosciences Holdings' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Senti Biosciences Holdings (SNTI), the current 3-1 Month Momentum % is -65.27% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
18GF Score
Get the complete analysis for SNTI
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNTI has been successfully added to your 
